Company Description
Traws Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States.
It has two clinical-stage programs, including narazaciclib, a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa study for the treatment of progressive K-Ras mutated non-small cell lung cancer.
The company also conducting a Phase II investigator-initiated study with rigosertib monotherapy in patients with advanced/metastatic squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa.
It has a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib in China.
The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024.
Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
| Country | United States |
| Founded | 1998 |
| IPO Date | Jul 25, 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 17 |
| CEO | Dr. Werner Cautreels Ph.D. |
Contact Details
Address: 12 Penns Trail Newtown, Pennsylvania 18940 United States | |
| Phone | 267-759-3680 |
Stock Details
| Ticker Symbol | TRAW |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| CIK Code | 0001130598 |
| ISIN Number | US68232V8019 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Steven M. Fruchtman M.D. | President and Chief Scientific Officer of Oncology |
| Mark Patrick Guerin CPA | Chief Financial Officer |
| Dr. Iain D. Dukes DPHIL, M.A., Ph.D. | Executive Chairman |
| Dr. Werner Cautreels Ph.D. | Chief Executive Officer and Director |
| Dr. Nikolay Savchuk Ph.D. | Chief Operating Officer and Director |
| Dr. Victor Moyo M.D. | Chief Medical Officer |
| Robert Redfield M.D. | Chief Medical Officer |
| C. David Pauza Ph.D. | Chief Scientific Officer of Virology |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 16, 2024 | D | Notice of Exempt Offering of Securities |
| Apr 16, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 16, 2024 | 8-K | Current Report |
| Apr 8, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Apr 4, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 4, 2024 | 8-K | Current Report |
| Apr 1, 2024 | 10-K | Annual Report |
| Mar 14, 2024 | 144 | Filing |
| Mar 14, 2024 | 144 | Filing |
| Feb 8, 2024 | 144 | Filing |